Epithelioid Hemangioendothelioma: Understanding Your Pathology Report

Section Editor: Bibianna Purgina MD FRCPC
November 10, 2026


Print this article

Epithelioid hemangioendothelioma (EHE) is a rare cancer that starts from endothelial cells, the cells that line the inside of blood vessels. It is a type of sarcoma, which is a cancer that starts in the body’s connective tissues. EHE most often develops in the liver, lungs, bones, or soft tissues such as fat and muscle, and most people who are diagnosed with it are adults.

Epithelioid hemangioendothelioma varies widely from person to person. Many tumors grow very slowly and stay stable for years, while a smaller number grow faster and spread to other parts of the body. The findings in your pathology report help your care team understand which pattern your tumor is likely to follow.

This article explains what epithelioid hemangioendothelioma is, how the diagnosis is confirmed, and what the gene fusion, risk features, margins, and stage in your pathology report mean. Our articles on angiosarcoma and Kaposi sarcoma describe other cancers that start from blood vessel cells.

Who gets epithelioid hemangioendothelioma?

Epithelioid hemangioendothelioma is very rare. Fewer than 1 in a million people are diagnosed with it each year. It can occur at almost any age, but most people are diagnosed between their 30s and their 60s, and it is uncommon in children.

EHE that starts in the liver is more common in women, who make up about two-thirds of people with liver EHE. Tumors that carry a less common gene change, called a YAP1::TFE3 fusion, tend to occur in younger adults. This gene change is explained in the section on causes below.

Where in the body does epithelioid hemangioendothelioma develop?

Epithelioid hemangioendothelioma can start almost anywhere in the body, because blood vessels are found in every organ. The liver is the most common site, followed by the lungs, bones, and soft tissues. Less often, it starts in the skin, the lining around the lungs (the pleura), or other organs.

EHE in the skin and soft tissues is usually a single tumor. EHE in the liver, lungs, or bones is often multifocal, which means there are several tumors at the time of diagnosis. More than half of people with EHE have more than one tumor when they are first diagnosed. Genetic studies suggest that these tumors often come from one original tumor that has spread, rather than many separate cancers.

What causes epithelioid hemangioendothelioma?

A gene fusion causes epithelioid hemangioendothelioma. A fusion forms when a piece of one gene breaks off and joins a piece of another gene. The result is a new hybrid gene that does not exist in normal cells. This change happens by chance inside the tumor cells during a person’s life, so it is not inherited and cannot be passed on to children.

About 9 in 10 tumors carry a fusion between two genes called WWTR1 and CAMTA1, and about 1 in 20 carry a fusion between YAP1 and TFE3 instead. The proteins made from WWTR1 and YAP1 normally act like switches that tell a cell when to grow. In healthy cells, a control system called the Hippo pathway turns these switches off when growth should stop. The fusion protein escapes this control, so the growth signal stays switched on and the cells keep dividing.

No lifestyle or environmental risk factors for epithelioid hemangioendothelioma are known.

What are the symptoms of epithelioid hemangioendothelioma?

The symptoms of epithelioid hemangioendothelioma depend on where the tumor is growing. Because many tumors grow slowly, some people have no symptoms, and the tumor is found on a scan done for another reason. When symptoms do occur, they may include:

  • Soft tissue. A lump that may be painful, or swelling when a tumor growing inside a vein blocks the flow of blood.
  • Liver. Pain in the upper right side of the abdomen, tiredness, or weight loss, and sometimes a buildup of fluid in the abdomen.
  • Lungs. A cough, chest pain, or shortness of breath, and sometimes fluid around the lungs, called a pleural effusion.
  • Bone. Pain in the affected bone, or less often a fracture when the tumor weakens the bone.

How is the diagnosis made?

A pathologist diagnoses epithelioid hemangioendothelioma by examining a tissue sample under a microscope. The tumor is usually first seen on a CT scan, MRI, or ultrasound. A sample is then removed with a needle biopsy guided by imaging, or the whole tumor is removed in an operation called an excision.

Under the microscope, the tumor is made of rounded epithelioid cells. These cells grow in thin cords, strands, and small nests. They sit in a pale background tissue that looks bubbly or glassy, which pathologists describe as myxohyaline stroma. Many tumor cells contain a small clear bubble, called an intracytoplasmic vacuole. The bubble is the cell’s attempt to form a tiny blood vessel, and it sometimes holds a red blood cell. The tumor often starts inside or around a blood vessel and spreads out into the nearby tissue.

Because the tumor cells look like carcinoma cells, the pathologist uses special tests to show they are blood vessel cells. The main test is immunohistochemistry, described in the next section. Many laboratories also perform molecular testing to look for the WWTR1::CAMTA1 or YAP1::TFE3 fusion. The test may be fluorescence in situ hybridization (FISH), an RNA-based test, or next-generation sequencing (NGS). Finding the fusion confirms the diagnosis, which is especially helpful when the tumor looks unusual under the microscope.

Once epithelioid hemangioendothelioma is confirmed, imaging is used to find every site of disease. This usually includes CT of the chest, abdomen, and pelvis, and sometimes MRI or PET. The next section describes the stains used to confirm the diagnosis.

Immunohistochemistry

Immunohistochemistry uses antibodies to show which proteins tumor cells make. In epithelioid hemangioendothelioma, it is used to prove that the tumor cells are endothelial cells and to rule out a carcinoma or another vascular tumor. Your report may list some or all of these results:

  • CD31 and ERG. These are the most reliable markers of blood vessel cells, and a positive result supports a vascular tumor such as EHE.
  • CD34, FLI1, and D2-40. These markers are usually positive and further support that the tumor cells are endothelial.
  • CAMTA1. This stain is positive in the nucleus of about 85 to 90 percent of tumors, and a positive result strongly suggests the WWTR1::CAMTA1 fusion. A negative result does not rule out EHE, because tumors with the YAP1::TFE3 fusion are negative.
  • TFE3. This stain is positive in tumors with the YAP1::TFE3 fusion. Some tumors with the WWTR1::CAMTA1 fusion are also positive, so this stain is supportive rather than definitive.
  • Keratins. Keratins are often negative, but some tumors are weakly positive. A positive keratin result does not mean the tumor is a carcinoma when the vascular markers are also positive.
  • EMA. EMA is usually negative or only weakly positive, which helps separate EHE from a carcinoma.

Stains vary by laboratory, and not every case needs every stain.

What are the different types of epithelioid hemangioendothelioma?

The current World Health Organization classification (5th edition, 2020) and the College of American Pathologists (CAP) soft tissue protocol divide epithelioid hemangioendothelioma into types based on the gene fusion. Your report may name the type in the diagnosis line:

  • EHE with WWTR1::CAMTA1 fusion. This is the most common type, accounting for about 9 in 10 tumors. It shows the classic microscopic appearance of cords of cells in a pale background.
  • EHE with YAP1::TFE3 fusion. This type accounts for about 1 in 20 tumors and tends to affect younger adults. The cells usually have more pink cytoplasm, grow in larger solid nests, and form more obvious blood vessel channels. Studies disagree about whether this type behaves better or worse than the WWTR1::CAMTA1 type.
  • EHE, NOS. NOS stands for “not otherwise specified,” and this label is used when fusion testing was not done or did not give a result. It does not mean the tumor is less certain or more serious.

Older reports may write the fusion with a dash, such as WWTR1-CAMTA1, instead of a double colon. Both forms mean the same thing.

Histologic grade

Epithelioid hemangioendothelioma is not graded. Your pathology report will not include a grade number, and this is expected for this diagnosis.

Instead of a grade, the pathologist describes the microscopic features linked to how EHE behaves. These features may appear on your report:

  • Mitotic count. The number of dividing cells, called mitotic figures, counted in a set area of the tumor. Most EHE has very few mitotic figures, and a higher mitotic rate is linked to a higher risk of spread.
  • Nuclear atypia. How abnormal the center of each cell looks. Most EHE shows little atypia, and marked atypia is linked to faster growth.
  • Necrosis. Areas of dead tumor cells, called necrosis. Necrosis is uncommon in EHE and is seen more often in faster-growing tumors.
  • Solid growth. Sheets of tumor cells rather than the usual thin cords. A small number of tumors grow this way, and they can look like angiosarcoma under the microscope.

For EHE in soft tissue, two features together are used to estimate risk. A tumor larger than 3 cm with more than 3 mitotic figures in 50 microscope fields is described as high risk. A tumor without either feature is described as low risk. Some reports use phrases such as “EHE with atypical features” or “high-risk EHE” for these tumors.

Tumor size

The size of an epithelioid hemangioendothelioma is measured in centimeters (cm), and the final size is measured on the tumor removed during surgery rather than on a biopsy. Size is one of the two features used to estimate the risk of spread for EHE in soft tissue, with 3 cm as the important cutoff. Size is also used to decide the tumor stage (pT), with cutoffs at 5, 10, and 15 cm for tumors in the trunk, arms, and legs.

When there are several tumors, the report usually gives the size of the largest one and may also say how many tumors were found.

Tumor extension

Epithelioid hemangioendothelioma in soft tissue often starts in or around a blood vessel and can grow into nearby structures as it enlarges. This spread beyond the original site is called tumor extension. The pathologist examines the tissue removed during surgery to see whether tumor cells have grown into nearby muscle, bone, nerves, larger blood vessels, or organs. Extension into nearby structures can increase the tumor stage (pT) for tumors of the head and neck. It may also affect planning for further surgery or radiation therapy.

Lymphovascular invasion

Lymphovascular invasion means tumor cells have entered a blood vessel or lymphatic channel. For most cancers, this is a separate finding that increases the risk of spread. Epithelioid hemangioendothelioma starts from the cells that line blood vessels, and it often grows inside a vein or along the vessel wall. Tumor cells inside vessels are therefore part of how this tumor normally grows, so lymphovascular invasion is not usually reported as a separate risk feature for EHE.

Surgical margins

A margin is the cut edge of the tissue removed during surgery for epithelioid hemangioendothelioma. The pathologist checks every margin for tumor cells under the microscope. The current CAP soft tissue protocol (version 4.2.0.0, June 2024) reports margins in the following ways:

  • Negative margin. No tumor cells are seen at the cut edge, which suggests the tumor was completely removed. The report also gives the distance from the tumor to the closest margin. A wider rim of normal tissue lowers the risk of the tumor coming back in the same place.
  • Positive margin. Tumor cells are seen at the cut edge, which means some tumor may remain in the body. Your care team may discuss further surgery, radiation therapy, or close monitoring.

Some reports also list every margin that is less than 0.5 cm from the tumor. When more than one tumor is removed, as in some liver or lung operations, the margins are described for each tumor.

Lymph nodes

Lymph nodes are small immune organs that filter fluid from tissues throughout the body. Epithelioid hemangioendothelioma spreads to lymph nodes uncommonly, but it does happen. Lymph nodes are therefore not routinely removed and are usually taken only when they appear enlarged or suspicious on imaging.

When lymph nodes are examined, the report states how many were examined and whether any contain tumor cells. Tumor in a lymph node changes the nodal stage from pN0 to pN1, as described in the staging section.

Biomarker and molecular testing

For most patients with epithelioid hemangioendothelioma, there are currently no biomarker tests that directly guide the choice of a specific targeted drug. The molecular test usually performed looks for the WWTR1::CAMTA1 or YAP1::TFE3 fusion. It is used to confirm the diagnosis and type, described above, rather than to direct treatment. Research into drugs that block the effects of these fusions is ongoing.

When the disease is growing or causing symptoms, clinicians may perform broader molecular profiling with next-generation sequencing. This testing can find other genetic changes that might make a patient eligible for a clinical trial. Your oncologist can discuss whether profiling is useful in your situation. Learn more about these tests in our Biomarkers section.

Pathologic stage (pTNM)

Pathologic stage describes the size and spread of epithelioid hemangioendothelioma based on the tissue examined by the pathologist. The AJCC Cancer Staging Manual, 8th edition, stages soft tissue tumors using the pTNM system. This remains the current edition for soft tissue sarcoma and includes tumor stage (pT) and nodal stage (pN). Spread to distant organs (M) is usually determined by imaging rather than by the pathologist.

TNM staging does not fit every case of EHE. The CAP protocol notes that EHE with many tumors in the chest or abdomen is not well suited to pTNM staging. For EHE of the liver or lungs, the report may instead describe the size of the largest tumor and how many tumors and organs are involved. Tumors that start in bone are staged with a separate bone system.

Tumor stage (pT)

The pT categories depend on where the tumor started. The letter “m” may be added to the pT stage, as in pT2(m), when there is more than one tumor.

Trunk and extremities (arms, legs, chest wall, abdominal wall):

  • pT1. The tumor is 5 cm or smaller.
  • pT2. The tumor is more than 5 cm but not more than 10 cm.
  • pT3. The tumor is more than 10 cm but not more than 15 cm.
  • pT4. The tumor is more than 15 cm.

Head and neck:

  • pT1. The tumor is 2 cm or smaller.
  • pT2. The tumor is more than 2 cm but not more than 4 cm.
  • pT3. The tumor is more than 4 cm.
  • pT4. The tumor has grown into nearby structures such as bone, the eye socket, major blood vessels, or the brain.

For tumors at any site:

  • pT0. No tumor is found in the tissue removed.
  • pTX. The tumor cannot be reliably assessed, for example when it was removed in several pieces and its size cannot be measured.

Nodal stage (pN)

  • pN0. No tumor cells are found in the lymph nodes examined.
  • pN1. Tumor cells are found in one or more regional lymph nodes.
  • pNX. No lymph nodes were sent for examination, which is common for EHE because lymph nodes are not routinely removed.

The pathologic stage differs from the overall stage group. Your oncologist assigns the overall stage group after combining the pathology results with imaging.

What is the prognosis?

The prognosis for epithelioid hemangioendothelioma ranges widely, from tumors that never cause harm to tumors that spread and shorten life. Many people live for many years with stable disease, even when more than one organ is involved. The main factors that shape the outlook are:

  • Location. EHE limited to the skin has an excellent outcome. When EHE is limited to soft tissue, about 9 in 10 people are alive five years after diagnosis. The figure is closer to 6 or 7 in 10 for EHE of the liver and about 4 or 5 in 10 for EHE of the lungs.
  • Tumor size and mitotic count. For EHE in soft tissue, people with low-risk tumors very rarely die of the disease. Among people with high-risk tumors, which are larger than 3 cm with a higher mitotic count, about 6 in 10 are alive at five years.
  • Fluid around the lungs or in the abdomen. Tumor involving the lining of the chest or abdomen, especially when they cause fluid buildup, are linked to a less favorable outlook.
  • Spread to other organs. About 1 in 5 soft tissue tumors spread, most often to the lungs, lymph nodes, liver, or bone. Spread does not always mean rapid progression, because many tumors with spread still grow slowly.
  • Margin status. A negative margin lowers the risk that the tumor will come back in the same place where it was removed.
  • Atypical features. Marked atypia, necrosis, and solid growth are linked to faster growth.

Even a tumor that looks bland under the microscope can come back or spread years later. For this reason, follow-up with regular imaging continues for many years after diagnosis.

What happens after the diagnosis?

Once pathology confirms epithelioid hemangioendothelioma, the next steps depend on several factors. These include where the tumor is, how many sites are involved, whether it is causing symptoms, and the risk features on the report. A sarcoma team usually plans care. This team may include a surgical oncologist or orthopedic oncologist, a medical oncologist, a radiation oncologist, and a liver or thoracic surgeon. An international expert consensus published in 2021 is widely used to guide these decisions. Options the team may consider include:

  • Surgery. When a single tumor or a small number of tumors can be removed, surgery is the main treatment. The goal is to remove the whole tumor with negative margins.
  • Liver transplantation. For EHE involving many sites in the liver but no other organs, a liver transplant may be considered in selected patients.
  • Active surveillance. Many people with multiple tumors that are stable and not causing symptoms are watched closely with regular scans. Treatment begins if the tumors grow or cause symptoms, and this approach avoids treatment side effects while the disease is quiet.
  • Radiation therapy. Radiation may be considered for a tumor that cannot be safely removed with surgery, such as some tumors in bone.
  • Medications. No drug has yet been approved specifically for EHE, and standard sarcoma chemotherapy is often less effective for this tumor. For disease that is growing or causing symptoms, oncologists often consider sirolimus. Sirolimus is an mTOR inhibitor, which is a drug that blocks a signal cells use to grow. It is used off-label, meaning it is approved for other conditions but not specifically for EHE. Chemotherapy may be considered for faster-growing tumors.
  • Clinical trials. Because EHE is rare, clinical trials are an important way for patients to receive new treatments. As of 2026, trials are testing new forms of sirolimus and other drugs in EHE. Your oncologist can tell you whether a trial is open to you.

Follow-up usually includes scans every few months at first, then less often if the disease stays stable. Because epithelioid hemangioendothelioma can return many years later, follow-up often continues long term.

Questions to ask your doctor

  • Where did my tumor start, and is there more than one tumor?
  • Which organs are involved?
  • Was fusion testing done, and does my tumor have the WWTR1::CAMTA1 or the YAP1::TFE3 fusion?
  • Does my report say whether the tumor is low-risk or high-risk?
  • How large is the tumor, and what is the mitotic count?
  • Does my tumor show atypia, necrosis, or solid growth?
  • Were the margins negative, and how close was the tumor to the nearest margin?
  • Were any lymph nodes examined, and did they contain tumor?
  • Is there fluid around my lungs or in my abdomen, and does it affect my outlook?
  • Is active surveillance an option for me, or does my tumor need treatment now?
  • Would molecular profiling with next-generation sequencing be useful in my situation?
  • Am I eligible for any clinical trials for epithelioid hemangioendothelioma?
  • How often will I need scans, and for how many years?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?